pISSN 2508-6235 eISSN 2508-7576

Download original image
Fig. 3. (A) Change in glycosylated hemoglobin (HbA1c) with different doses of tirzepatide and comparators in SURPASS programme. (B) Change in weight with different doses of tirzepatide and comparators in SURPASS programme and SURMOUNT-1 study. All data is presented as efficacy estimand. *P< 0.05 for the estimated treatment difference with each dose of tirzepatide vs. placebo and/or active comparator. T2DM, type 2 diabetes mellitus; Met, metformin; SGLT2i, sodium-glucose co-transporter 2 inhibitor; SU, sulfonylurea; OAD, oral antidiabetic drug; Tirz, tirzepatide; Pbo, placebo; Sema, semaglutide; Degl, insulin degludec; Glar, insulin glargine; Dula, dulaglutide.
J Obes Metab Syndr 2023;32:25~45 https://doi.org/10.7570/jomes22067
© JOMES